Family history and cancer risk study (FOREST): A clinical trial assessing electronic patient-directed family history input for identifying patients at risk of hereditary cancer.

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Kathleen F Mittendorf, Harris T Bland, Justin Andujar, Natasha Celaya-Cobbs, Clasherrol Edwards, Meredith Gerhart, Gillian Hooker, Mryia Hubert, Sarah H Jones, Dana R Marshall, Rachel A Myers, Siddharth Pratap, S Trent Rosenbloom, Azita Sadeghpour, R Ryanne Wu, Lori A Orlando, Georgia L Wiesner
{"title":"Family history and cancer risk study (FOREST): A clinical trial assessing electronic patient-directed family history input for identifying patients at risk of hereditary cancer.","authors":"Kathleen F Mittendorf, Harris T Bland, Justin Andujar, Natasha Celaya-Cobbs, Clasherrol Edwards, Meredith Gerhart, Gillian Hooker, Mryia Hubert, Sarah H Jones, Dana R Marshall, Rachel A Myers, Siddharth Pratap, S Trent Rosenbloom, Azita Sadeghpour, R Ryanne Wu, Lori A Orlando, Georgia L Wiesner","doi":"10.1016/j.cct.2024.107714","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hereditary cancer syndromes cause a high lifetime risk of early, aggressive cancers. Early recognition of individuals at risk can allow risk-reducing interventions that improve morbidity and mortality. Family health history applications that gather data directly from patients could alleviate barriers to risk assessment in the clinical appointment, such as lack of provider knowledge of genetics guidelines and limited time in the clinical appointment. New approaches allow linking these applications to patient health portals and their electronic health records (EHRs), offering an end-to-end solution for patient-input family history information and risk result clinical decision support for their provider.</p><p><strong>Methods: </strong>We describe the design of the first large-scale evaluation of an EHR-integrable, patient-facing family history software platform based on the Substitutable Medical Applications and Reusable Technologies on Fast Healthcare Interoperability Resources (SMART on FHIR) standard. In our study, we leverage an established implementation science framework to evaluate the success of our model to facilitate scalable, systematic risk assessment for hereditary cancers in diverse clinical environments in a large pragmatic study at two sites. We will also evaluate the success of the approach to improve the efficiency of downstream genetic counseling resulting from pre-counseling pedigree generation.</p><p><strong>Conclusions: </strong>Our research study will provide evidence regarding a new care delivery model that is scalable and sustainable for a variety of medical centers and clinics.</p><p><strong>Trial registration: </strong>This study was registered on ClinicalTrials.gov under NCT05079334 on 15 October 2021.</p>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":" ","pages":"107714"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cct.2024.107714","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hereditary cancer syndromes cause a high lifetime risk of early, aggressive cancers. Early recognition of individuals at risk can allow risk-reducing interventions that improve morbidity and mortality. Family health history applications that gather data directly from patients could alleviate barriers to risk assessment in the clinical appointment, such as lack of provider knowledge of genetics guidelines and limited time in the clinical appointment. New approaches allow linking these applications to patient health portals and their electronic health records (EHRs), offering an end-to-end solution for patient-input family history information and risk result clinical decision support for their provider.

Methods: We describe the design of the first large-scale evaluation of an EHR-integrable, patient-facing family history software platform based on the Substitutable Medical Applications and Reusable Technologies on Fast Healthcare Interoperability Resources (SMART on FHIR) standard. In our study, we leverage an established implementation science framework to evaluate the success of our model to facilitate scalable, systematic risk assessment for hereditary cancers in diverse clinical environments in a large pragmatic study at two sites. We will also evaluate the success of the approach to improve the efficiency of downstream genetic counseling resulting from pre-counseling pedigree generation.

Conclusions: Our research study will provide evidence regarding a new care delivery model that is scalable and sustainable for a variety of medical centers and clinics.

Trial registration: This study was registered on ClinicalTrials.gov under NCT05079334 on 15 October 2021.

家族史与癌症风险研究(FOREST):一项临床试验,评估患者在电子指导下输入家族病史以识别有遗传性癌症风险的患者。
背景:遗传性癌症综合征导致终生罹患早期侵袭性癌症的风险很高。及早识别高危人群可以采取降低风险的干预措施,从而提高发病率和死亡率。直接从患者处收集数据的家庭健康史应用程序可减轻临床预约中的风险评估障碍,如医疗服务提供者对遗传学指南缺乏了解以及临床预约时间有限等。新方法可将这些应用程序与患者健康门户网站及其电子健康记录(EHR)连接起来,为患者输入家族病史信息提供端到端解决方案,并为医疗服务提供者提供风险结果临床决策支持:方法:我们描述了对可整合电子病历、面向患者的家族史软件平台的首次大规模评估设计,该平台基于快速医疗保健互操作性资源上的可替代医疗应用和可重复使用技术(SMART on FHIR)标准。在我们的研究中,我们将利用已建立的实施科学框架来评估我们的模型是否成功,以促进在两个地点进行的大型实用研究中,在不同的临床环境中对遗传性癌症进行可扩展的系统性风险评估。我们还将评估该方法在提高咨询前血统生成所产生的下游遗传咨询效率方面是否成功:我们的研究将为各种医疗中心和诊所提供可扩展、可持续的新医疗服务模式:本研究于 2021 年 10 月 15 日在 ClinicalTrials.gov 上注册,注册号为 NCT05079334。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信